paroxetine (Q408471)

17 November 2015

Paroxetine Structural Formulae V.1.svg
483 × 444; 15 KB

0 references

mass

329.143 dalton

1 reference

paroxetine (English)

19 October 2016

C₁₉H₂₀FNO₃

1 reference

paroxetine (English)

19 November 2016

C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4

1 reference

paroxetine (English)

19 November 2016

C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4

1 reference

paroxetine (English)

19 November 2016

20 milligram

route of administration

oral administration

1 reference

Anatomical Therapeutic Chemical Classification System

1 reference

14 February 2018

1 reference

14 February 2018

1 reference

14 February 2018

World Health Organisation international non-proprietary name

paroxetine (English)

1 reference

Paroxetine (English)

medical condition treated

19 January 2016

obsessive-compulsive disorder

2 references

13 December 2016

2 October 2018

1 reference

13 December 2016

1 reference

13 December 2016

1 reference

13 December 2016

social anxiety disorder

1 reference

post-traumatic stress disorder

13 December 2016

2 references

13 December 2016

generalized anxiety disorder

2 October 2018

1 reference

2 October 2018

anxiety disorder

1 reference

2 October 2018

anxiety

1 reference

significant drug interaction

2 October 2018

isocarboxazid

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

procarbazine

1 reference

High-priority drug–drug interactions for use in electronic health records

(±)-deprenyl

1 reference

High-priority drug–drug interactions for use in electronic health records

tranylcypromine

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

Possible paroxetine-zolpidem interaction.

desmopressin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clopidogrel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

eptifibatide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

iloprost

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prostacyclin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tirofiban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

abciximab

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prasugrel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ticagrelor

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cangrelor

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aspirin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rivaroxaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rac-warfarin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

acenocoumarol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

phenindione

1 reference

A reference set of clinically relevant adverse drug-drug interactions

apixaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(S)-duloxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sertraline

1 reference

A reference set of clinically relevant adverse drug-drug interactions

venlafaxine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluvoxamine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluoxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

A reference set of clinically relevant adverse drug-drug interactions

trimipramine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

amitriptyline

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(S)-duloxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(E/Z)-doxepin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sertraline

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluvoxamine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluoxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

imipramine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clomipramine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pethidine

paralytic ileus

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tapentadol

paralytic ileus

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

trimipramine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

amitriptyline

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(E/Z)-doxepin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

venlafaxine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

imipramine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clomipramine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

bupropion

seizure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

risperidone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluvoxamine

screaming

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluoxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

solute carrier family 6 member 4

subject has role

enzyme inhibitor

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

4790

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

17 August 2016

route of administration

oral administration

0 references

legal status (medicine)

boxed warning

1 reference

reference URL

Australian pregnancy category D

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category D

1 reference

imported from Wikimedia project

English Wikipedia

described at URL

https://cpe.org.uk/our-news/mhra-class-2-medicines-recall-paroxetine-40mg-film-coated-tablets-crescent-pharma-limited/

1 reference

reference URL

https://cpe.org.uk/our-news/mhra-class-2-medicines-recall-paroxetine-40mg-film-coated-tablets-crescent-pharma-limited/

MHRA Class 2 Medicines Recall: Paroxetine 40mg Film Coated Tablets (Crescent Pharma Limited) - Community Pharmacy England (British English)

selective serotonin reuptake inhibitor

24 October 2024

subject has role

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

D017374

cytochrome P-450 CYP2D6 inhibitors

15 March 2018

1 reference

Medical Subject Headings

MeSH descriptor ID

D017374

second-generation antidepressive agents

15 March 2018

1 reference

Institute for Safe Medication Practices

Medical Subject Headings

15 March 2018

PARoxetine

1 reference

reference URL

https://www.ismp.org/recommendations/tall-man-letters-list

2 September 2022

0 references

0 references

Paroxetine

0 references

Identifiers

InChI

InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1

1 reference

paroxetine (English)

19 November 2016

2 references

paroxetine (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

61869-08-7

2 references

https://commonchemistry.cas.org/detail?cas_rn=61869-08-7

paroxetine (English)

19 November 2016

7 April 2021

1 reference

Paroxetine (English)

19 November 2016

2 references

paroxetine (English)

19 November 2016

Reaxys registry number

7467879

1 reference

paroxetine (English)

19 October 2016

mapping relation type

2 references

PAROXETINE (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1

1 reference

PAROXETINE (English)

19 November 2016

2 references

inferred from InChIKey

MSBNK-Athens_Univ-AU152606

1 reference

MassBank accession ID

SM855502

0 references

0 references

MSBNK-Waters-WA001105

0 references

MSBNK-Waters-WA001106

0 references

MSBNK-Waters-WA001107

0 references

MSBNK-Waters-WA001108

0 references

MSBNK-Waters-WA001109

0 references

SPLASH

splash10-001i-2409000000-077fb077fbf0e4210f51

0 references

splash10-0006-8900000000-0a273deac3c7836cdc76

0 references

HSDB ID

7175

1 reference

Hazardous Substances Data Bank

28 October 2019

PAROXETINE (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.112.096

27 December 2018

ECHA Substance Infocard ID

(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-piperidine (English)

quotation

CAS no.: 61869-08-7 (English)

100.112.096

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.112.096

27 December 2018

(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-piperidine (English)

quotation

CAS no.: 61869-08-7 (English)

1 reference

Guide to Pharmacology Ligand ID

Paroxetine (English)

publication date

17 November 2015

4790

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

4790

paroxetine (English)

19 November 2016

Paroxetine

0 references

0 references

0 references

1 reference

paroxetine (English)

19 November 2016

1 reference

Human Metabolome Database ID

HMDB0014853

2 references

based on heuristic

inferred from InChIKey

2 references

paroxetine (English)

19 November 2016

32Q7TW8BX7

1 reference

MedlinePlus drug identifier

a698032

0 references

PatientsLikeMe treatment ID

0 references

1 reference

paroxetine (English)

19 November 2016

0 references

1 reference

1 reference

paroxetine (English)

19 October 2016

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

paroxetine (English)

19 October 2016

0 references

1 reference

28 October 2013

1 reference

9 July 2020

Microsoft Academic ID

0 references

1 reference

26 January 2022

1 reference

5I6X (English)

19 October 2016

1 reference

3V5W (English)

19 October 2016

1 reference

4JLT (English)

19 October 2016

1 reference

4MM4 (English)

19 October 2016

1 reference

4L9I (English)

UK Parliament thesaurus ID

19 October 2016

12745

subject named as

Paroxetine

0 references

UMLS CUI

C0070122

1 reference

paroxetine (English)

19 November 2016

0 references

WordNet 3.1 Synset ID

03897548-n

1 reference